Multi-center study on the prevalence of hypothyroidism in patients with hypercholesterolemia

Endocrine Journal

Volumn 58, Issue 6, 2011, Pages 449-457

  Tagami, Tetsuya ^a   Kimura, Hironori ^b   Ohtani, Sumire ^c   Tanaka, Tsuyoshi ^d   Tanaka, Takashi ^d   Hata, Shiro ^e   Saito, Miho ^f   Miyazaki, Yasushi ^g   Araki, Rika ^h   Tanaka, Masami ⁱ   Yonezawa, Kazuya ^j   Sawamura, Morio ^k   Ise, Takuyuki ^l   Ogo, Atsushi ^m   Shimbo, Takuro ⁿ   Shimatsu, Akira ^a   Naruse, Mitsuhide ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c SAITAMA NATIONAL HOSPITAL   (Japan)

^d National Hospital Organization Mie Chuo Medical Center   (Japan)

^e Ureshino Medical Center   (Japan)

^f Yoshinogawa   (Japan)

^g Misato Kenwa Hospital   (Japan)

^h MIE NATIONAL HOSPITAL   (Japan)

ⁱ TENRI HOSPITAL   (Japan)

^j National Hospital Organization Hakodate Hospital   (Japan)

^k NATIONAL HOSPITAL ORGANIZATION   (Japan)

^l NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

^m NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

ⁿ NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

more..

Author keywords

Dyslipidemia; Hypercholesterolemia; Subclinical hypothyroidism

Indexed keywords

ANTILIPEMIC AGENT; COLESTILAN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRINKING BEHAVIOR; FATTY LIVER; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHYROIDISM; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; THYROID FUNCTION TEST; THYROTOXICOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; HYPOTHYROIDISM; JAPAN; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 79960005822     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K11E-012     Document Type: Article

References (44)

1. Jacobson TA (2009) Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 5:507-518.
2. Duntas LH, Wartofsky L (2007) Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence? Thyroid 17:1075-1084.
3. Klein I, Ojamaa K (2001) Thyroid hormone and the cardiovascular system. N Engl J Med 344:501-509.
4. Keating Fr Jr, Parkin TW, Selby JB, Dickinson LS (1961) Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 3:364-381.
5. Series JJ, Biggart EM, O'Reilly DS, Packard CJ, Shepherd J (1988) Thyroid dysfunction and hypercholesterolaemia in the general population of Glasgow, Scotland. Clin Chim Acta 172:217-221.
6. O'Kane MJ, Neely RD, Trimble ER, Nicholls DP (1991) The incidence of asymptomatic hypothyroidism in new referrals to a hospital lipid clinic. Ann Clin Biochem 28:509-511.
7. Glueck CJ, Lang J, Tracy T, Speirs J (1991) The common finding of covert hypothyroidism at initial clinical evaluation for hyperlipoproteinemia. Clin Chim Acta 201:113-122.
8. Diekman T, Lansberg PJ, Kastelein JJ, Wiersinga WM (1995) Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 155:1490-1495.
9. Tsimihodimos V, Bairaktari E, Tzallas C, Miltiadus G, Liberopoulos E, Elisaf M (1999) The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 9:365-368.
10. Pirich C, Mullner M, Sinzinger H (2000) Prevalence and relevance of thyroid dysfunction in 1922 cholesterol screening participants. J Clin Epidemiol 53:623-629.
11. Surks MI, Ortiz EO, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and managemnt. JAMA 291:228-238.
12. Cappola AR, Ladenson PW (2003) Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 88:2438-2444.
13. Luboshitzky R, Heter P (2004) Cardiovascular risk factors in middle-aged women with subclinical hypothyroidism. Neuro Endocrinol Lett 25:262-266.
14. Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC (2006) Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med 119:541-551.
15. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V (2005) Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 165:2467-2472.
16. Silva JE (2005) Intermediary metabolism and the sympathoadrenal system in hypothyroidism. In: Braverman LE, Utiger RD (eds) Werner & Ingbar's The Thyroid, A fundamental and clinical text, 9th edition. Lippincott Williams & Wilkins, Philadelphia, pp 817-829.
17. Bakker O, Hudig F, Meijssen S, Wiersinga WM (1998) Effects of triiodothyronine and amiodarone on the promoter of the LDL receptor gene. Biochem Biophys Res Commun 249:517-521.
18. Shin DJ, Osborne TF (2003) Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SRBP-2). J Biol Chem 278:34114-34118.
19. Pykalisto O, Goldberg AP, Brunzell JD (1976) Reversal of decreased human adipose tissue lipoprotein lipase and hypertriglyceridemia after treatment of hypothyroidism. J Clin Endocrinol Metab 43:591-600.
20. Valdemarsson S, Hedner P, Nilsson-Ehle P (1982) Reversal of decreased hepatic lipase and lipoprotein lipase activities after treatment of hypothyroidism. Eur J Clin Invest 12:423-428.
21. Valdemarsson S, Hansson P, Hedner P, Nilsson-Ehle P (1983) Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations. Acta Endocrinol (Copenh) 104:50-56.
22. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. (2000) The Colorado thyroid disease prevalence study. Arch Intern Med 160:526-534.
23. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH (2001) Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis 155:195-200.
24. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE (2002) Serum TSH, T4, and thyroid autoantibodies in the United States population (1988-1994): National health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab 87:489-499.
25. Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, Usa T, Ashizawa K, Yokoyama N, Maeda R, Nagataki S, Eguchi K (2004) Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 89:3365-3370.
26. Takashima N, Niwa Y, Mannami T, Tomoike H, Iwai N (2007) Characterization of subclinical thyroid dysfunction from cardiovascular and metabolic viewpoints: the Suita study. Circ J 71:191-195.
27. Michalopoulou G, Alevizaki M, Piperingos G, Mitsibounas D, Mantzos E, Adamopoulos P, Koutras DA (1998) High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol 138:141-145.
28. Iqbal A, Jorde R, Figenschau Y (2006) Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinincal hypothyroidism: the Tromso Study. J Intern Med 260:53-61.
29. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B (2001) TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 86:4860-4866.
30. Caraccio N, Ferranini E, Monzani F (2002) Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 87:1533-1538.
31. Monzani F, Caraccio N, Kozakowa M, Dardano A, Vittone F, Virdis A, Taddei S, Palombo C, Ferrannini E (2004) Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab 89:2099-2106.
32. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU (2007) The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab 92:1715-1723.
33. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway ECL (1984) Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med 101:18-24.
34. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA, Lindstedt G (1988) A double-blind cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin Endocrinol (Oxf) 29:63-67.
35. Jaeschke R, Guyatt G, Gerstein H, Patterson C, Molloy W, Cook D, Harper S, Griffith L, Carbotte R (1996) Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 11:744-749.
36. Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M, Dore CJ, Finer N (2002) A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med 112:348-354.
37. Sari R, Kemal Balci M, Altunbas H & Karayalcin U (2003) The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol 59:258-262.
38. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE & Kyriazopoulou VE (2006) Thyroid function in humans with morbid obesity. Thyroid 16:73-78.
39. De Pergola G, Ciampolillo A, Paolotti S, Trerotoli P, Giorgino R (2007) Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol 67:265-269.
40. Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L, Jorgensen T (2005) Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 90:4019-4024.
41. Asvold BO, Bjøro T, Vatten LJ (2009) Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab 94:5023-5027.
42. Manji N, Boelaert K, Sheppard MC, Holder RL, Gough SC, Franklyn JA (2006) Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. Clin Endocrinol 64:125-128.
43. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE, Kyriazopoulou VE (2006) Thyroid function in humans with morbid obesity. Thyroid 16:73-78.
44. Gullu S, Emral R, Bastemir M, Parkes AB, Lazarus JH (2005) In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis. Eur J Endocrinol 153:41-48.